文献速递造血干细胞移植与细胞治疗

MAGIC复合缓解:整合临床与生物标志物参数用于急性GVHD的新型终点

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.
PubMed 文献 · Blood Adv · 2025-01-01

研究纳入1135例接受急性GVHD系统治疗的患者,利用第28天MAGIC复合评分(MCS)0或1定义MAGIC复合缓解(MCR),在验证队列(n=309)中比较MCR与临床缓解(CRO)对6个月非复发死亡(NRM)的预测能力。MCR预测6个月NRM的曲线下面积优于CRO(0.77 vs 0.69,P=.014),并能重新分类临床应答者与非应答者。

要点

  • 第28天MCS 0或1定义为MAGIC复合缓解(MCR)。
  • 验证队列中MCR预测6个月NRM的AUC为0.77 vs CRO 0.69(P=.014)。
  • MCR将13%临床应答者重分类为无应答,其NRM为34.3% vs 6.8%。

核心结论

  • MCR较CRO更准确预测6个月NRM,支持MCR作为未来临床试验中评估GVHD长期控制与生存的替代终点。

研究设计与样本

  • 分析1135例接受急性GVHD系统治疗的患者数据,创建第4个MCS类别,采用以6个月NRM为终点的分类回归树模型,并在验证队列(n=309)中评估。

主要发现

  • 验证队列中MCR预测6个月NRM的AUC为0.77 vs CRO 0.69(P=.014),且MCR的阴性预测值和阳性预测值更高。
  • 213例临床应答者中28例(13%)经MCR重分类为无应答,其NRM为34.3% vs 6.8%(P<.001)。
  • 96例临床无应答者中29例(30%)经MCR重分类为应答,其NRM为7.6% vs 50.7%(P<.001)。

关键数值与推荐

  • 第28天MCS 0或MCS 1定义为MAGIC复合缓解(MCR)。

临床怎么用

  • 原文结论支持将MCR作为未来临床试验中评估GVHD长期控制与生存的替代终点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Changes in the clinical symptoms of acute graft-versus-host disease (GVHD) are currently used to assess treatment responses. The Mount Sinai Acute GVHD International Consortium (MAGIC) consortium has recently revealed that the integration of serum biomarkers with clinical symptoms at the onset of treatment in a MAGIC composite score (MCS) more accurately predicts treatment response and 6-month nonrelapse mortality (NRM) than clinical symptoms alone. In this study, we evaluated whether the integration of serum biomarkers and clinical symptoms on day 28 (D28) would also better predict NRM than clinical response only (CRO). We analyzed data from 1135 patients receiving systemic treatment for acute GVHD and created a fourth MCS category for patients with complete resolution of symptoms and low-risk clinical biomarkers on D28. Using a classification and regression tree model with 6-month NRM as the end point, we identified status of MCS 0 or MCS 1 at D28 as responses, which we termed the MAGIC composite response (MCR). In the validation cohort (n = 309), MCR more accurately predicted 6-month NRM than CRO (area under the curve: 0.77 vs 0.69; P = .014) and demonstrated higher negative and positive predictive values. MCR correctly reclassified both clinical nonresponders and responders: 28 of 213 clinical responders (13%) became nonresponders with fivefold higher NRM (34.3% vs 6.8%, P < .001) and a larger group (29/96, 30%) of clinical nonresponders became responders with sixfold lower NRM (7.6% vs 50.7%, P < .001). These findings support the use of MCR as a superior surrogate end point for long-term GVHD control and survival in future clinical trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Akahoshi Y, Portelli J, Katsivelos N, et al. The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD. Blood Adv. 2025. PMID: 40815797. doi:10.1182/bloodadvances.2025017116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。